Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users.

Acta neuropsychiatrica - 25 Mar 2025

Hietala Elina, Solismaa Anssi, Lähteenvuo Markku, Ahola-Olli Ari V, Häkkinen Katja, Suokas Kimmo, Isometsä Erkki, Suvisaari Jaana, Kieseppä Tuula, Holm Minna, Tiihonen Jari, Lönnqvist Jouko, Hietala Jarmo, Wegelius Asko, Lahdensuo Kaisla, Haaki Willehard, Kampman Olli

Abstract excerpt

Non-adherence and negative attitudes towards medication are major problems in treating psychotic disorders. Cytochrome P450 2D6 (CYP2D6) contributes to the metabolism of aripiprazole and risperidone, and variations in CYP2D6 activity may affect treatment response or adverse effects. However, the impact of these variations on adherence and medication attitudes is unclear. This study investigates the relationships...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Attitude to Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Finland

Share to Medication Adherence

Share to Psychotic Disorders

Share to Risperidone

Share to Self Report

Source

Open in PubMed Open full text

Identifiers

PMID: 40130908
DOI: 10.1017/neu.2025.11
PMCID: PMC13130289

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users.PMID 40130908Read ↗

Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole.Semantic proximity Read ↗

Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities.Semantic proximity Read ↗

Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.Semantic proximity Read ↗

A Preliminary Investigation of Genetic Variants Linked to Aripiprazole-Induced Adverse EffectsSemantic proximity Read ↗

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.Semantic proximity Read ↗

Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.Semantic proximity Read ↗

CYP2D6 Genotypes Do Not Affect Clozapine Levels in a Large, Multicenter Cohort: Time Has Come to Revise Food and Drug Administration's Clozapine Packet Insert.Semantic proximity Read ↗

CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.Semantic proximity Read ↗

Clinical effects of CYP2D6 phenoconversion in patients with psychosis.Semantic proximity Read ↗

Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.Semantic proximity Read ↗

Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trialSemantic proximity Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.